A controlled study with taltrimide and sodium valproate: valproate effective in partial epilepsy

Acta Neurologica Scandinavica
M IivanainenP J Neuvonen

Abstract

Taltrimide was compared with valproate and placebo in 17 patients with intractable epilepsy being on carbamazepine monotherapy. Taltrimide (400 mg/day), valproate (1000 mg/day) or placebo were added to the treatment for periods of 3 months using a randomized cross-over design. Serum carbamazepine concentrations remained within the therapeutic range throughout the trial. Thirteen patients completed the study. In partial epilepsy of 7 the seizure frequency was reduced by 27% during valproate (p less than 0.05), compared with placebo, while no improvement was found during taltrimide. In 6 with primary generalized epilepsy, the number of seizures was reduced by 49% during taltrimide and by 38% during valproate, but neither effect was significant, compared with placebo. Headache was reported by 3 patients while on taltrimide. One with hypersensitivity history developed petecchiae and nasal bleeding during taltrimide and, therefore, the treatment was stopped. The three other interruptions were independent of taltrimide. Thus, the only statistically significant effect in this study was that of valproate in partial epilepsy.

References

Jan 1, 1983·Acta Neurologica Scandinavica. Supplementum·M Iivanainen, H Savolainen
Jan 1, 1983·Acta Neurologica Scandinavica. Supplementum·K Abild, M Dam
Jan 1, 1984·Journal of Pharmaceutical Sciences·L AndersenS S Oja
Feb 18, 1983·European Journal of Pharmacology·S S OjaG Gothóni
Jan 1, 1983·Neurochemistry International·I B LindénS S Oja
Jan 1, 1985·Neurochemistry International·K Nakagawa, R J Huxtable

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.